Healthcare / Medical DevicesKOSDAQ
$3070.00
-60.00 (-1.92%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-15.7B · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$60.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-48.6%
↓Gross Margin
43.7%
↓Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+42.1%
FCF CAGR
—
FCF margin
-427.0%
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.69B · net income $-19.46B · FCF $-15.75B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.69B | $3.69B | $2.50B | $3.12B | $1.29B |
| Net Income | $-19.46B | $-19.46B | $-20.17B | $-21.56B | $-19.24B |
| EBITDA | $-15.63B | $-15.63B | $-16.51B | $-19.12B | $-16.76B |
| EPS | -1052.00 | -1052.00 | -1220.00 | -1305.00 | -1167.00 |
| Gross Margin | 43.7% | 43.7% | 36.4% | 31.7% | 43.7% |
| Operating Margin | -422.0% | -422.0% | -647.2% | -720.6% | -1558.8% |
| Net Margin | -527.6% | -527.6% | -807.7% | -691.4% | -1496.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.24 | 0.24 | 2.55 | 0.05 | 0.04 |
| Current Ratio | 4.13 | 4.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-15.75B | $-15.75B | $-13.46B | $-22.49B | $-18.02B |
| Returns | |||||
| ROE | -48.6% | -48.6% | -308.8% | -119.0% | -48.2% |
| Valuation | |||||
| P/B | 1.42 | 1.42 | 16.00 | 4.65 | 2.01 |
| Growth & Yield | |||||
| Revenue Growth | 47.7% | 47.7% | -19.9% | 142.5% | — |
| EPS Growth | 13.8% | 13.8% | 6.5% | -11.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1220.00 → -1052.00
Residual
-12.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.